Fanyi Mo

505 total citations · 1 hit paper
11 papers, 401 citations indexed

About

Fanyi Mo is a scholar working on Immunology, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Fanyi Mo has authored 11 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 5 papers in Biomedical Engineering and 3 papers in Molecular Biology. Recurrent topics in Fanyi Mo's work include Phagocytosis and Immune Regulation (4 papers), Nanoplatforms for cancer theranostics (4 papers) and Immune cells in cancer (2 papers). Fanyi Mo is often cited by papers focused on Phagocytosis and Immune Regulation (4 papers), Nanoplatforms for cancer theranostics (4 papers) and Immune cells in cancer (2 papers). Fanyi Mo collaborates with scholars based in United States and China. Fanyi Mo's co-authors include Zhaoting Li, Quanyin Hu, Yixin Wang, Jun Liu, Yu Chen, Paul M. Sondel, Yingyue Ding, Seungpyo Hong, Jianxin Wang and Wen Li and has published in prestigious journals such as Chemical Society Reviews, Nature Communications and Nature Nanotechnology.

In The Last Decade

Fanyi Mo

10 papers receiving 397 citations

Hit Papers

Depletion of tumor associated macrophages enhances local ... 2022 2026 2023 2024 2022 40 80 120

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fanyi Mo United States 8 185 174 164 111 73 11 401
Armin Ahmadi United States 12 120 0.6× 233 1.3× 153 0.9× 126 1.1× 77 1.1× 23 511
Mengwen Huang China 9 85 0.5× 144 0.8× 109 0.7× 68 0.6× 43 0.6× 14 309
Jialin Lai China 9 169 0.9× 178 1.0× 109 0.7× 41 0.4× 58 0.8× 11 391
Qianqian Zhu China 5 340 1.8× 230 1.3× 139 0.8× 74 0.7× 207 2.8× 14 584
Samuel S.K. Lam United States 11 134 0.7× 136 0.8× 280 1.7× 151 1.4× 40 0.5× 17 502
Xiandi Meng China 9 116 0.6× 431 2.5× 104 0.6× 66 0.6× 91 1.2× 18 600
Erica N. Bozeman United States 13 161 0.9× 209 1.2× 211 1.3× 176 1.6× 121 1.7× 20 524
Lujia Huang China 9 183 1.0× 148 0.9× 150 0.9× 87 0.8× 79 1.1× 14 400
Emad I. Wafa United States 13 116 0.6× 171 1.0× 107 0.7× 87 0.8× 94 1.3× 19 404

Countries citing papers authored by Fanyi Mo

Since Specialization
Citations

This map shows the geographic impact of Fanyi Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fanyi Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fanyi Mo more than expected).

Fields of papers citing papers by Fanyi Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fanyi Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fanyi Mo. The network helps show where Fanyi Mo may publish in the future.

Co-authorship network of co-authors of Fanyi Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Fanyi Mo. A scholar is included among the top collaborators of Fanyi Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fanyi Mo. Fanyi Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Li, Zhaoting, et al.. (2025). Engineering pyroptotic vesicles as personalized cancer vaccines. Nature Nanotechnology. 20(8). 1108–1118. 7 indexed citations
2.
Li, Zhaoting, Fanyi Mo, Kai Guo, et al.. (2024). Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. Med. 5(4). 348–367.e7. 14 indexed citations
3.
Li, Zhaoting, Yueyang Deng, Honghao Sun, et al.. (2023). Redox modulation with a perfluorocarbon nanoparticle to reverse Treg-mediated immunosuppression and enhance anti-tumor immunity. Journal of Controlled Release. 358. 579–590. 17 indexed citations
4.
Wang, Yixin, et al.. (2023). Nano-STING agonist-decorated microrobots boost innate and adaptive anti-tumor immunity. Nano Research. 16(7). 9848–9858. 13 indexed citations
5.
Wang, Yixin, Wen Li, Zhaoting Li, et al.. (2023). Active recruitment of anti–PD-1–conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy. Science Advances. 9(13). eadf6854–eadf6854. 33 indexed citations
6.
Wang, Yixin, et al.. (2023). Chemically engineering cells for precision medicine. Chemical Society Reviews. 52(3). 1068–1102. 46 indexed citations
7.
Li, Zhaoting, Fanyi Mo, Yixin Wang, et al.. (2022). Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. Nature Communications. 13(1). 6321–6321. 94 indexed citations
8.
Li, Zhaoting, Yingyue Ding, Jun Liu, et al.. (2022). Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nature Communications. 13(1). 1845–1845. 148 indexed citations breakdown →
9.
Gentner, Dedre, et al.. (2021). Verbs are More Metaphoric than Nouns: Evidence from the Lexicon. eScholarship (California Digital Library). 43(43). 1 indexed citations
10.
Wang, Yixin, Zhaoting Li, Fanyi Mo, Zhen Gu, & Quanyin Hu. (2021). Engineered platelets: Advocates for tumor immunotherapy. Nano Today. 40. 101281–101281. 25 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026